Remdesivir’s EU Approval For COVID-19 Due Within Days
Gilead's Antiviral Drug Gets CHMP OK
You may also be interested in...
EMA Assessing If Kidney Injury In COVID-19 Patients Is Linked To Remdesivir
While an EU panel is examining reports of acute kidney injury in some COVID-19 patients taking remdesivir, researchers conducting a UK-based study are preparing to update their systematic benefit-risk analysis of the drug as and when more safety data becomes available.
EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.
Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.